2022 Rome Action Plan on Paediatric HIV & TB
Penta commits to:
225. Setting up a data collection system in collaboration with the Ministry of Health of Uganda to monitor the safety and effectiveness of dolutegravir in the paediatric population.
226. Study the PK, safety and virological/immunological impact of monoclonal anti-HIV antibodies in combination with antivirals in children responding to therapy, by 2025.
227. Promoting the use of real-world data in combination with clinical trial data for regulatory